FDA OKs Adagene’s ADG-106 for Clinical Trial in Solid Tumors, Non-Hodgkin’s Lymphoma
News
Adagene soon will initiate a Phase 1 clinical trial testing its lead product, ADG-106, in patients who have advanced solid tumors and non-Hodgkin’s lymphoma, the company announced. This follows the U.S. ... Read more